Mayo Clinic Study May Help Physicians Determine How Patients Will Respond to Multiple Myeloma Therapy

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, say Mayo Clinic researchers who presented results of several clinical trials at the 53nd annual meeting of the American Society of Hematology Dec. 10-13 in San Diego.

MORE ON THIS TOPIC